CVS explores options including potential break-up, sources say
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500 volatile in choppy trading; Mideast deal, SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Morgan Stanley Reiterates Overweight Rating on CVS Health (CVS)
October 2, 2024 6:56 AM EDTMorgan Stanley analyst Erin Wright reiterated an Overweight rating and $65.00 price target on CVS Health (NYSE: CVS).
The analyst comments "Latest Hypothetical SOTP Suggests Upside, But Variables Remain: In light of a recent Reuters report (here) noting that the CVS Board may be considering potential options to break up CVS retail and insurance businesses, we detail our latest SOTP analysis, including key assumptions below. CVS declined to... More
Leerink Partners Reiterates Market Perform Rating on CVS Health (CVS)
October 1, 2024 6:28 AM EDTLeerink Partners analyst Michael Cherny reiterated a Market Perform rating on CVS Health (NYSE: CVS).
The analyst comments "Bottom Line: Following our initial note highlighting the potential of CVS evaluating strategic alternatives including a break-up of the company (Initial CVS note; WSJ report) we wanted to include some quick views on the potential plusses and potential minuses of a breakup. This isn't meant to be comprehensive and is intentionally short form given the fluidity of the reported situation. But we thought it was important to highlight how this... More
Evercore ISI Reiterates Outperform Rating on CVS Health (CVS)
October 1, 2024 5:54 AM EDTEvercore ISI analyst Elizabeth Anderson reiterated an Outperform rating and $62.00 price target on CVS Health (NYSE: CVS).
The analyst comments "What happened? After the market close today, Reuters reported that CVS is exploring options, including a potential break-up of the company to... More
